Clinical Trial Search

Primary: Total Nasal Symptom Score (TNSS) Area Under the Curve (AUC) — 2.46; 2.81; 3.66; 3.10 Total Nasal Symptom Score * Hour — p=0.314

Primary: Scores on a Scale (Average of Total Symptom Scores) — 7.02; 8.30; 7.87 Scores on a scale — p=<0.05

Primary: Time to Early Asthmatic Response (EAR) Upon Controlled Cat Allergen Challenge in an Environmental Exposure Unit (EEU) on Day 8 — 51; NA Minutes — p== 0.0083

Primary: Change in Basophil Surface IgE — -95; -10 percentage of basophil surface IgE

Primary: Change in Ocular Itch Score From Baseline — -1.5; -1.5 units on a scale — p=0.532

Primary: Area Under the Curve (AUC) of Percent Change in Forced Expiratory Volume in 1 Second (FEV1) Over a 1-hour Cat Allergen Exposure From Pre-challenge at Week 16 — 15.03…

Primary: The the Size of the 8 Late-phase Skin Response — 54; 0 percentage decline from NAC-1

Primary: Number of Subjects With AEs — 5; 12 participants

Primary: Number of Reported Adverse Events (AEs) — 9; 1; 1; 2 Events

Primary: Mean Combined Score (CS) Consisting of TRSS/8+Allergy Medication Score[AMS]) — 1.99; 1.91; 1.93 units on a scale

Primary: Asthma Severity as Measured by the Asthma Severity Score (Averaged up to 36 Months) — 21.95; 25.68; 27.72; 27.85 score on a scale — p=0.38

Primary: Change From Baseline in the Mean Asthma Control Questionnaire (ACQ) Score at Day 92 — 2.63; 2.72; 2.62; 2.72 units on a scale — p=0.573

Primary: Difference in Expression of Epithelial miRNAs (in Read Counts) 24 Hours After Allergen-challenge as Compared to 24 Hours After Diluent Challenge in Participants With…

Primary: True Allergy (Consistent With an IgE-mediated Reaction) — 135 Allergies

Primary: Average Daily Total Combined Rhinitis Symptom and Medication Score (TCRS) During the Primary Efficacy Assessment Period — 3.4; 4.4 score on a scale — p=<0.0001

Primary: Number and Seriousness of Both Local and Systemic Adverse Reactions — 2; 1; 0; 1 adverse reactions number

Primary: Percentage of Subjects With a Successful Treatment Response — 12.0; 45.8; 48.0 percentage of participants — p=0.005

Primary: Percentage of Subjects in the Xolair® (Omalizumab) Group vs. Placebo Group Developing Clinical Tolerance to Milk — 46.4; 34.5 Percent of participants — p=0.42

Primary: Bronchial Threshold to Allergen Challenge From Baseline to 12-18 Months of Treatment — 75.0; 69.5; 141.4; 74.8 cumulative breath units

Primary: The Total Number of Differentially Expressed Transcripts. — 119; 49 transcripts

Primary: Treatment Emergent Adverse Events — 13; 3; 81; 2 number of adverse events per arm

Primary: Duration of Suppressive Effect of Desloratadine After Discontinuation of a 1-week Treatment — 5; 4; NA Days

Primary: The Level of Allergen Consumed Post-oral Immunotherapy — 6; 300 milligrams

Primary: The Difference in Area (cm2) of the Wheal Size in Histamine Skin Test Response During Treatment With Olopatadine Compared to Placebo. — 0.461; 0.464 cm2 — p=0.57

Primary: Change in Mean Total Nasal Symptom Score (TNSS) From Baseline to 12 Months Between Cockroach SCIT and Placebo — -1.02; -0.79 score on a scale — p=0.63

Primary: Number of Subjects With at Least One Treatment-emergent Adverse Event (TEAE) — 223 subjects

Primary: Mast Cell Activation Test Results for Validation Group — 6; 2; 0; 4 Participants

Primary: Mean Ocular Itching at Onset of Action — 0.38; 0.47; 0.59; 1.91 units on a scale

Primary: Number of Subjects Who Completed Desensitization Protocol — 6; 12 participants

Primary: Wheal Response — 6.8 mm